A study evaluated the effectiveness of DNA methylation triage using the WID-qCIN test in combination with HPV16/18 genotyping for cervical cancer screening in a real-world population of 28,017 women aged ≥30 years who attended cervical screening in Stockholm between January and March 2017. The WID-qCIN test assessed DNA methylation in three genes (DPP6, RALYL, GSX1) and was combined with HPV16/18 genotyping to triage HPV-positive women. The results showed that the WID-qCIN/HPV16/18 combination detected 93.4% of cervical intraepithelial neoplasia grade 3 (CIN3) and 100% of invasive cervical cancer (CC) cases, compared to 69.4% of CIN2+ cases detected by cytology. The WID-qCIN/HPV16/18 combination also predicted 69.4% of incident CIN2+ cases, significantly higher than the 18.2% predicted by cytology. The study found that the WID-qCIN/HPV16/18 combination required fewer colposcopy referrals to detect one CIN2+ case compared to cytology-based triage. The study supports the use of WID-qCIN/HPV16/18 as an improved triage strategy for HPV-positive women. The study highlights the potential of DNA methylation-based triage to improve the accuracy and efficiency of cervical cancer screening, reducing the number of colposcopy referrals needed. The findings suggest that DNA methylation-based triage could be a valuable tool in cervical cancer screening, particularly in resource-limited settings. The study also notes that the WID-qCIN/HPV16/18 combination detected seven out of eight invasive CC cases in women who were cytology-negative, indicating its potential to identify high-risk cases. The study concludes that DNA methylation-based triage could significantly reduce the number of invasive cancers in HPV-screened populations. The study was conducted in a real-world setting, minimizing biases and providing valuable insights into the effectiveness of DNA methylation-based triage in cervical cancer screening. The study also highlights the importance of continued research and development in improving cervical cancer screening methods.A study evaluated the effectiveness of DNA methylation triage using the WID-qCIN test in combination with HPV16/18 genotyping for cervical cancer screening in a real-world population of 28,017 women aged ≥30 years who attended cervical screening in Stockholm between January and March 2017. The WID-qCIN test assessed DNA methylation in three genes (DPP6, RALYL, GSX1) and was combined with HPV16/18 genotyping to triage HPV-positive women. The results showed that the WID-qCIN/HPV16/18 combination detected 93.4% of cervical intraepithelial neoplasia grade 3 (CIN3) and 100% of invasive cervical cancer (CC) cases, compared to 69.4% of CIN2+ cases detected by cytology. The WID-qCIN/HPV16/18 combination also predicted 69.4% of incident CIN2+ cases, significantly higher than the 18.2% predicted by cytology. The study found that the WID-qCIN/HPV16/18 combination required fewer colposcopy referrals to detect one CIN2+ case compared to cytology-based triage. The study supports the use of WID-qCIN/HPV16/18 as an improved triage strategy for HPV-positive women. The study highlights the potential of DNA methylation-based triage to improve the accuracy and efficiency of cervical cancer screening, reducing the number of colposcopy referrals needed. The findings suggest that DNA methylation-based triage could be a valuable tool in cervical cancer screening, particularly in resource-limited settings. The study also notes that the WID-qCIN/HPV16/18 combination detected seven out of eight invasive CC cases in women who were cytology-negative, indicating its potential to identify high-risk cases. The study concludes that DNA methylation-based triage could significantly reduce the number of invasive cancers in HPV-screened populations. The study was conducted in a real-world setting, minimizing biases and providing valuable insights into the effectiveness of DNA methylation-based triage in cervical cancer screening. The study also highlights the importance of continued research and development in improving cervical cancer screening methods.